Rovi expands its collaboration with Moderna. The Spanish pharmaceutical company announced on Monday, April 12th, that it is strengthening its collaboration for the manufacture of the active ingredient of Moderna’s Covid-19 vaccine. To this end, new industrial investment will be made at the Spanish group’s facilities in Granada.
This investment consists of the installation of a new line to support the production phases of the active ingredient of the mRNA vaccine, which are previous and additional to the formulation, filling, and finishing of the vaccine, as the company has informed the Spanish Securities and Exchange Commission (Cnmv). This line would have a production capacity equivalent to more than 100 million doses per year and is expected to start supplying markets outside the United States in the third quarter of 2021.
With this action, Rovi expands the activities it carries out in the manufacturing process of the Moderna vaccine: it will participate in the manufacture of the active ingredient as well as in its formulation, bottling and final packaging, prior to its distribution for administration to patients.
Read more about the agreement between Rovi and Moderna and find the most important business news of the day with our companion app, Born2Invest.
Rovi will carry out a new industrial investment in the facilities that the Spanish group has in Granada
“We are very happy about the collaboration with Moderna, whose vaccine against Covid-19 is one of the best positioned in the race to solve this health crisis; We are very excited that Rovi will go a step further and participate in the manufacture of the vaccine’s active ingredient, as further integration in the production process would allow us to support Moderna in its large-scale supply more broadly,” said Rovi’s CEO, Juan López-Belmonte.
Rovi is a pan-European specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and commercialization of small molecules and specialty biologics. The company has subsidiaries in Portugal, Germany, United Kingdom, Italy, France and Poland, and has a diversified portfolio of more than forty marketed products, including its reference product, Bemiparin, which is already marketed in 58 countries around the world.
Rovi posted a net profit of $72.7 million (€61.1 million) in 2020, 55% higher than in 2019, when it earned $46.7 million (€39.3 million). Rovi’s operating income increased by 10% in 2020 compared to the previous year, to $500 million (€420 million).
These results are due, according to the group, to the strength of the third-party manufacturing business, which grew by 39% in sales following the agreement for Moderna’s Covid-19 vaccine, as well as the specialty pharmaceuticals business, whose turnover increased by 4%.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
MATIC Share Price Forecast: What Does Polygon Expect in the Current Bear Market?
Cryptocurrencies such as Bitcoin and Polygon have a close correlation with stocks. In most cases, they rise when leading indexes...
Coima sgr’s Porta Nuova Centrale Fund Secures €173.5 Million Green Financing
Coima sgr, founded and led by CEO Manfredi Catella, ended 2021 with assets under management up 6 percent to $9.74...
Canopy Growth Sales Disappoint, Stock Under Pressure
Just a week before announcing its latest numbers, Canopy announced its latest acquisition: the purchase of California-based cannabis extraction and...
Solidarity Day 2022: Ganzourgou Producers Offer 2.6 Tons of Food to Vulnerable People
Regarding the selection criteria of vulnerable people, Ambroise Ouédraogo said that his association collaborates with the provincial directorate of Social...
Ford Chooses Almussafes over Germany for the Production of Electric Models
Thus, the Valencian factory will be the fifth Spanish factory to produce all-electric models. Stellantis manufactures electric models at its...
Biotech2 weeks ago
Satellos Bioscience’s Stem Cell Signaling Research Could Turn the Tables on Muscular Dystrophies
Cannabis2 weeks ago
Luis Figo Launches His Brand of CBD Products
Featured2 weeks ago
Stock Markets Have Officially Entered Bear Territory
Business2 weeks ago
The Influx of Federal Funds Is Spurring Rail Improvements Nationwide